Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies

Sponsor

Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.

Attendees find out:

How innovation in upstream technology will deliver process robustness and titer enhancement
How to optimize and effectively scale up downstream bioprocess workflows in order to capitalize on increased upstream yields
What is the latest thinking and innovation in developing the analytics needed to improve both the quality and efficiency of viral vector manufacture for gene therapy
New regulatory paradigm for accelerated cell and gene therapy product development.
Key points of future focus for further investment and collaboration